Combining cyclin-dependent kinase (CDK) inhibitors with heat shock protein 90 (HSP-90) inhibitors presents a promising approach to destabilizing hypoxia-inducible factor 1-alpha (HIF1α) and inhibiting cancer cell growth. This evidence concerns the gene HIF1A and cancer.